PubMed Health⌕ Search

Biomedical subjects

Z Y Tang

Publications and source records attributed to Z Y Tang.

At least 127 records · Page 7Linked to original sources
PubMed1986

The changing role of surgery in the treatment of primary liver cancer.

For decades, the role of surgery in the treatment of primary liver cancer (PLC) was important but limited. However, a comparison of pathologically proven PLC during the three periods 1958-1966, 1967-1975, and 1976-1984 revealed that as a result of alpha fetoprotein (AFP) serosurvey, changing concepts in surgical oncology, and introduction of new surgical modalities, the role of surgery has become greater. The increasing proportion of subclinical PLC (0, 7.2, and 21.2%) has favored the increasing series resection rate (16.1, 34.7, and 39.6%) and palliative surgery (13.7, 17.0, and 29.8%). The results indicated that early resection, reoperation for subclinical recurrence, resection of huge PLC in stages, and combination of palliative surgery other than resection might be responsible for the increasing 5-year survival rate (1.7, 7.1, and 19.5%) in the entire series.

Adenoma, Bile Duct↗
PubMed1986

[Natural killer cell activity of the peripheral blood in patients with hepatocellular carcinoma].

Using 125IudR labeled K562 cells as target cells, peripheral blood of 56 patients with hepatocellular carcinoma (HCC) was studied for natural killer cell (NK cell) activity. The results show that the NK cell activity is in normal range of 53.97 +/- 4.42% and 50.85 +/- 3.55% in stages I and II of HCC but in stage III, the NK cell activity is markedly depressed, only 31.63 +/- 5.55%. The NK cell activity is much lower in HCC patients with metastasis than without metastasis (33.67 +/- 5.37% versus 50.22 +/- 2.79%). So is it in patients with high concentration than with low concentration of AFP except patients with advanced lesion and low concentration of AFP. After effective treatment, the NK cell activity increased in 10 of 11 patients treated with radical and palliative resection and in 6 of 9 after immunotherapy with BCG, mixed bacterial vaccine or interferon.

Adult↗
PubMed1986

[Randomized clinical trial of cis-platinum diamminedichloride (PDD) in the treatment of hepatocellular carcinoma (HCC)].

From Oct. 1982 to Apr. 1985, 82 patients with HCC proven by pathology were treated in our hospital. 43 treated by hepatic arterial perfusion, were randomized into PDD group: PDD 10 mg per day X 10, every 3 weeks; control group: fluorouracil (5-Fu) 250 mg per day X 4, every week and thio-tepa (TSPA) 10 mg, twice a week. The other 39 treated by intravenous chemotherapy, were also randomized into PDD group: PDD 20 mg per day X 5, every 3 weeks; control group: 5-Fu 500 mg and TSPA 10 mg, twice a week. The objective response rates were 31.8% (7/22) in PDD group and 23.8% (5/21) in control group by hepatic arterial perfusion, and 20.0% (4/20) in the former and 0% (0/19) in the latter who were treated intravenously. The median survivals were 8 months for all the patients receiving hepatic arterial perfusion, and 6 and 5 months for the intravenous PDD and its control group, respectively. The side effects and kidney toxicity of PDD were tolerable to the patients. It is observed that PDD is better than 5-Fu and TSPA in the treatment of HCC.

Carcinoma, Hepatocellular↗
PubMed1983

Nuclear antigen detected in hepatoma cell lines containing integrated hepatitis B virus DNA.

We identified, by anticomplement immunofluorescence, a nuclear antigen (hepatitis B virus-associated nuclear antigen [HBNA]) in two human hepatoma cell lines containing integrated hepatitis B virus DNA but not in three hepatoma cell lines lacking it. The antigen resembled neoantigens associated with the oncogenesis of certain papovaviruses, adenoviruses, and herpesviruses. Antibody to the antigen (anti-HBNA) was found in 7.3% of hepatitis B surface antigen-positive sera from patients with hepatocellular carcinoma but not in surface antigen-negative sera. The staining of HBNA was characterized by two patterns, reticular nuclear fluorescence and nucleolar fluorescence. The expression of HBNA did not parallel the production of extracellular hepatitis B surface antigen. Treatment of cells with proteinase K, RNase, DNase, or cycloheximide significantly diminished the staining of HBNA.

Animals↗